Stem Cells for Heart Failure: Another Disappointment

A phase 2 study of patients with advanced heart failure with reduced ejection fraction has negative results.

Researchers have explored mesenchymal precursor cells (MPCs) for promoting cardiac regeneration in individuals with failing ventricles, including those with advanced heart failure with reduced ejection fraction (HFrEF) requiring a left ventricular assist device (LVAD). A preliminary trial conducted in the NIH-sponsored Cardiothoracic Surgical Trials Network suggested that MPC therapy facilitated weaning from LVADs, at least temporarily. In this phase 2 trial (NCT02362646), the researchers enrolled 159 individuals with advanced HFrEF and scheduled for LVAD implantation (mean age, 56; 11% women; median LVEF, 15%; New York Heart Association class IV symptoms, 73%).

Participants were randomized in a 2:1 ratio to an intramyocardial injection duri…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)